[Featured Stock] Anigen Rises on Announcement of HLB Group Acquisition

As of 9:42 AM on the 11th, Anigen's stock price on the KOSDAQ market is recorded at 11,890 KRW, up 4.85% from the previous day's closing price. This is because HLB Group announced the acquisition of Anigen, a peptide new drug and material company, the day before. Anigen had recorded the upper price limit for two consecutive trading days on the 7th and 10th.

Earlier on the 10th, HLB Group announced that seven of its affiliates would participate in a third-party allotment paid-in capital increase of 15 billion KRW in Anigen, while also acquiring convertible bonds (CB) worth 5 billion KRW to take over management rights. Separately, financial investors (FI) will also acquire a paid-in capital increase of 5 billion KRW and CBs worth 35 billion KRW in Anigen.

Anigen possesses peptide manufacturing technology that has attracted attention as a glucagon-like peptide-1 (GLP-1) based obesity treatment.

Additionally, Anigen is currently pursuing certification for current Good Manufacturing Practice (cGMP) for its active pharmaceutical ingredient production facilities from the U.S. Food and Drug Administration (FDA). Once certified, it is expected to expand its peptide active pharmaceutical ingredient contract development and manufacturing organization (CDMO) business overseas.

HLB also expressed its intention to strengthen Anigen's CDMO business based on the 60 billion KRW capital injection this time.